Ubrelvy (ubrogepant) is currently still under patent protection, meaning its market exclusivity has not yet expired. It is not an expired drug.
When Does Ubrelvy's Patent Protection End?
The initial U.S. patent for Ubrelvy is expected to expire in 2031 [1]. However, patent expiration dates can be complex and are subject to various factors, including potential patent extensions and litigation. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines [1].
What Happens After a Drug Patent Expires?
Once a drug patent expires, it typically opens the door for generic manufacturers to produce and market their own versions of the medication. This process can lead to increased competition and often results in lower drug prices for consumers. For Ubrelvy, this means that after 2031, other companies may be able to launch generic ubrogepant.
Can Generic Ubrelvy Be Available Before Patent Expiry?
While the primary patent is set to expire in 2031, it is possible for generic versions to become available sooner under specific circumstances. These can include successful patent challenges by generic companies or settlement agreements between the brand-name manufacturer and generic challengers. However, such events are not guaranteed and depend on legal and regulatory processes.
Who Manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [2].
How Does Ubrelvy Work for Migraine?
Ubrelvy is a prescription medication used for the acute treatment of migraine with or without aura in adults [2]. It belongs to a class of drugs called gepants and works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pathways [3].
What are the Side Effects of Ubrelvy?
Common side effects of Ubrelvy may include nausea, fatigue, and dry mouth [2]. Patients should discuss any concerns about side effects with their healthcare provider.
What Other Treatments Are Available for Migraine?
Beyond Ubrelvy, other acute migraine treatments include triptans, ergots, and other gepants [3]. Preventive migraine therapies are also available for individuals experiencing frequent migraines.
How Does Ubrelvy Compare to Other Migraine Medications?
Ubrelvy offers an alternative to traditional triptans for acute migraine treatment and is particularly useful for patients who do not respond to or cannot take triptans due to cardiovascular risks [3]. As a gepant, it targets CGRP differently than triptans.
What is the Cost of Ubrelvy?
The cost of Ubrelvy can vary based on insurance coverage and pharmacy. Patients often use manufacturer coupons or patient assistance programs to help manage costs.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.ubrelvy.com/
[3] https://www.mayoclinic.org/drugs-supplements/ubrogepant-oral-tablet/drug-review/drg-20520511